News

RISE is a multicenter, randomized, double-masked, sham injection-controlled, 36-month Phase III study designed to assess the safety and efficacy profile of Lucentis in 377 patients with DME. The

TIBCO will now incorporate General Dynamics’ ViPS’ NAV-10 technology into its selected Foresight products. The NAV-10 Code Translation Suite is an integral part of the General Dynamics’ ICD-10

Inhibitex is developing a series of proprietary nucleotide inhibitors that target the RNA-dependent RNA polymerase (NS5b) of HCV. INX-189 is a protide of a 2′-C-methylguanosine analogue. Inhibitex believes

The FlexTab technology allows for a variety of fill materials, including powders, pellets, liquids, micro-tablets and tablets, and can even deliver separate liquid and powder active pharma ingredients

Axcan Pharma has completed the previously announced tender offer for the outstanding ordinary shares of Eurand for $587m. Axcan president and CEO Frank Verwiel said the combination of

The Morpheus SMART PICC 5F Dual Lumen Smart PICC power-injectable catheter power-injectable catheter is designed to provide a superior flow rate of 5ml/second for purposes of CT imaging.

The team fabricated an electrically responsive nanoporous membrane based on polypyrrole doped with the dodecylbenzenesulfonate anions (PPy/DBS) which was electropolymerized to the top and upper side walls of

Pradaxa (dabigatran etexilate) is Boehringer Ingelheim’s novel, oral direct thrombin inhibitor for stroke risk reduction in patients with non-valvular atrial fibrillation (AF). According to a statement, the Washington-based

The filing was accompanied by a priority review classification and a Prescription Drug User Fee Act (PDUFA) date of 17June, 2011. Apart from filing acceptance and assignment of